Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ NGAL Monoclonal Antibody (3B1C10)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA538281
Description
This antibody has been tested in direct-ELISA.
NGAL (Neutrophil gelatinase-associated lipocalin, lipocalin 2, siderocalin and neutrophil lipocalin) is a 25 kDa glycosylated single chain monomer and member of the lipocalin family of proteins that bind and transport small lipophilic molecules. NGAL is released by activated neutrophils, can form dimers and small amounts of higher oligomers, and complexes with matrix metalloproteinase 9 (MMP-9, gelatinase B). Low level expression of NGAL in a variety of epithelia may be increased in inflammation or cancers. Expression of NGAL in the kidney is dramatically increased by ischemic or nephrotoxic kidney injury.
Specifications
NGAL | |
Monoclonal | |
1.0 mg/mL | |
PBS with 50% glycerol and 0.03% ProClin 300; pH 7.4 | |
P80188 | |
LCN2 | |
Recombinant Human Neutrophil gelatinase-associated lipocalin protein. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG2b |
Immunohistochemistry, Immunohistochemistry (Paraffin), Western Blot | |
3B1C10 | |
Unconjugated | |
LCN2 | |
24p3; 25 kDa alpha-2-microglobulin-related subunit of MMP-9; alpha-2-microglobulin-related protein; Alpha-2U globulin-related protein; AW212229; HGNC:6526; HNL; LCN2; lipocalin 2; lipocalin 2 (oncogene 24p3); Lipocalin 24p3; Lipocalin2; Lipocalin-2; migration-stimulating factor inhibitor; MSFI; neutrophil gelatinase-associated lipocalin; NGAL; oncogene 24p3; OTTHUMP00000022240; p25; RP23-161B9.11; secreted inducible protein 24; Siderocalin; Siderocalin LCN2; Sip24; SV-40-induced 24P3 protein; uterocalin | |
Mouse | |
Protein G | |
RUO | |
3934 | |
-20°C or -80°C if preferred | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction